News & Events
News & Events
Celebrating the 20th Anniversary of the Institut Pasteur Korea, “Advancing as a Central Hub for Infectious Disease Preparedness and Response, Focusing on Treatments and Vaccines”
2024-06-10
Celebrating the 20th Anniversary of the Institut Pasteur Korea,
“Advancing as a Central Hub for Infectious Disease Preparedness and Response, Focusing on Treatments and Vaccines”
- Announced achievements in infectious disease R&D, highlighting the discovery of
“Advancing as a Central Hub for Infectious Disease Preparedness and Response, Focusing on Treatments and Vaccines”
- Announced achievements in infectious disease R&D, highlighting the discovery of
drug candidates and the advancement of infrastructure –
- Exploring Global Pandemic Preparedness Strategies with Global Experts,
Including Nobel Laureate Professor Charles M. Rice -
- Exploring Global Pandemic Preparedness Strategies with Global Experts,
Including Nobel Laureate Professor Charles M. Rice -
(Jun 7, 2024, Gyeonggi-do, Rep. of Korea) Institut Pasteur Korea (IPK) held a commemorative event on May 30 to celebrate its 20th anniversary, where it announced a strategy to ‘strengthen vaccine and treatment R&D to prepare for and respond to infectious diseases.’
In the ceremony, Sung Key Jang, CEO of IPK, presented a vision: "We will become a pivotal base for infectious disease preparedness and response by enhancing drug development capabilities accumulated over 20 years and strengthening mRNA vaccine R&D, thus generating results directly contributing to public health.”
In the achievement briefing, IPK’s 20-year history of contributing to infectious disease preparedness and response was introduced, including leading translational research connecting basic research to industrialization, creating excellent research results through the innovative drug discovery platform, and accelerating open innovation.
Congratulatory remarks were also made by those who contributed to the establishment and development of the research institute, including Chang Yune Lee, 1st Vice-Minister of the Ministry of Science and ICT; Hyundai Kim, Director General for Future Growth Industry Bureau of Gyeonggi Provincial Government; Odette Tomescu-Hatto, Executive Vice President of International Affairs of Institut Pasteur; Cheol-Soo Ahn, Member of the National Assembly of the Republic of Korea; Philippe Bertoux, Ambassador of France to the Republic of Korea; Yung-Bog Chae, Founding Chairman of the Institut Pasteur Korea Board of Directors; and Ulf Nehrbass, Founding CEO of Institut Pasteur Korea.
In addition, awards were given to employees who contributed to national development through science and technology promotion: Dr. Regis Grailhe, Head of the Technology Development Platform team, received the Order of Science and Technology Merit Jinbo Medal, while Mr. Jinhyun Park, Head of the Research Resource Support Center, Dr. Seungtaek Kim, Head of Zoonotic Virus Lab, and Mr. David Shum, Head of Screening Discovery Platform, received Commendations from the Minister of Science and ICT for their contributions to the promotion of science and technology.
The international symposium following, 'Overcoming Infectious Diseases: From Discovery to Preparedness, ' explored strategies to address future pandemics with a Nobel Prize laureate and global experts.
Charles M. Rice, Professor of the Laboratory of Virology and Infectious Disease at Rockefeller University and laureate of the 2020 Nobel Prize in Physiology or Medicine, presented the latest research results in viral hepatitis and novel strategies under the theme 'Chronic viral hepatitis and cancer: Insights from promising new models and approaches.’
A lecture continued to review cases and lessons learned from responding to the COVID-19 pandemic and prepare for the threat of another pandemic by Takaji Wakita, Director General of the National Institute of Infectious Diseases. Prof. Wakita shared COVID-19 research cases and achievements, focusing on responses and lessons learned during the COVID-19 pandemic.
Félix A. Rey, Professor at Institut Pasteur and Head of the Structural Virology Unit, shared insights on the topic 'From virus entry to sexual reproduction: class II membrane fusion proteins and their mechanism of action.'
Young Ki Choi, Managing Director of the Korea Virus Research Institute, presented on 'Severe Fever with Thrombocytopenia Syndrome Virus: Prevalence and its age-dependent pathogenesis.
Since it was established in 2004 through the Korea-France collaboration in science and technology, IPK has produced excellent results through basic and translational research on infectious diseases. In particular, IPK successfully developed Q203 (Telasevec), a drug candidate for drug-resistant tuberculosis, and licensed out to Qurient Co., Ltd., a spin-off company. Q203 is expected to proceed with clinical trial 2b this year. In addition, drug candidates for the treatment of major infectious diseases such as COVID-19, antibiotic-resistant bacterial infections, and hepatitis C were discovered and tech-transferred. Furthermore, IPK has pioneered in establishment of High-throughput Screening (HTS) and High Content Screening (HCS) platforms in a Biosafety Level 3 facility, accelerating open innovation and R&D for high-risk infectious diseases.
In the ceremony, Sung Key Jang, CEO of IPK, presented a vision: "We will become a pivotal base for infectious disease preparedness and response by enhancing drug development capabilities accumulated over 20 years and strengthening mRNA vaccine R&D, thus generating results directly contributing to public health.”
In the achievement briefing, IPK’s 20-year history of contributing to infectious disease preparedness and response was introduced, including leading translational research connecting basic research to industrialization, creating excellent research results through the innovative drug discovery platform, and accelerating open innovation.
Congratulatory remarks were also made by those who contributed to the establishment and development of the research institute, including Chang Yune Lee, 1st Vice-Minister of the Ministry of Science and ICT; Hyundai Kim, Director General for Future Growth Industry Bureau of Gyeonggi Provincial Government; Odette Tomescu-Hatto, Executive Vice President of International Affairs of Institut Pasteur; Cheol-Soo Ahn, Member of the National Assembly of the Republic of Korea; Philippe Bertoux, Ambassador of France to the Republic of Korea; Yung-Bog Chae, Founding Chairman of the Institut Pasteur Korea Board of Directors; and Ulf Nehrbass, Founding CEO of Institut Pasteur Korea.
In addition, awards were given to employees who contributed to national development through science and technology promotion: Dr. Regis Grailhe, Head of the Technology Development Platform team, received the Order of Science and Technology Merit Jinbo Medal, while Mr. Jinhyun Park, Head of the Research Resource Support Center, Dr. Seungtaek Kim, Head of Zoonotic Virus Lab, and Mr. David Shum, Head of Screening Discovery Platform, received Commendations from the Minister of Science and ICT for their contributions to the promotion of science and technology.
The international symposium following, 'Overcoming Infectious Diseases: From Discovery to Preparedness, ' explored strategies to address future pandemics with a Nobel Prize laureate and global experts.
Charles M. Rice, Professor of the Laboratory of Virology and Infectious Disease at Rockefeller University and laureate of the 2020 Nobel Prize in Physiology or Medicine, presented the latest research results in viral hepatitis and novel strategies under the theme 'Chronic viral hepatitis and cancer: Insights from promising new models and approaches.’
A lecture continued to review cases and lessons learned from responding to the COVID-19 pandemic and prepare for the threat of another pandemic by Takaji Wakita, Director General of the National Institute of Infectious Diseases. Prof. Wakita shared COVID-19 research cases and achievements, focusing on responses and lessons learned during the COVID-19 pandemic.
Félix A. Rey, Professor at Institut Pasteur and Head of the Structural Virology Unit, shared insights on the topic 'From virus entry to sexual reproduction: class II membrane fusion proteins and their mechanism of action.'
Young Ki Choi, Managing Director of the Korea Virus Research Institute, presented on 'Severe Fever with Thrombocytopenia Syndrome Virus: Prevalence and its age-dependent pathogenesis.
Since it was established in 2004 through the Korea-France collaboration in science and technology, IPK has produced excellent results through basic and translational research on infectious diseases. In particular, IPK successfully developed Q203 (Telasevec), a drug candidate for drug-resistant tuberculosis, and licensed out to Qurient Co., Ltd., a spin-off company. Q203 is expected to proceed with clinical trial 2b this year. In addition, drug candidates for the treatment of major infectious diseases such as COVID-19, antibiotic-resistant bacterial infections, and hepatitis C were discovered and tech-transferred. Furthermore, IPK has pioneered in establishment of High-throughput Screening (HTS) and High Content Screening (HCS) platforms in a Biosafety Level 3 facility, accelerating open innovation and R&D for high-risk infectious diseases.